Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with radiation and immune modulatory cocktail in cervical and uterine cancer
2016-001569-97Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Cervical Cancer (CC), endometrial cancer (EC) and uterine sarcoma, sponsored by Ghent University Hospital. Primary endpoint: Objective response rate at week 26 by irRC. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)uterine sarcoma
Beyond the preview
Go deeper on 2016-001569-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001569-97.